Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. Nature 629, 624–629 (2024).
Ghosh, S. et al. Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. Gut 74, 295–311 (2025).
He, X. et al. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Semin. Cancer Biol. 88, 187–200 (2023).
Bessadok, A., Mahjoub, M. A. & Rekik, I. Graph neural networks in network neuroscience. IEEE Trans. Pattern Anal. Mach. Intell. 45, 5833–5848 (2023).
He, X. H. et al. AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors. Acta Pharmacol. Sin. 44, 1–7 (2023).
Wenteler, A. et al. AI approaches for the discovery and validation of drug targets. Camb. Prism. Precis. Med. 2, e7 (2024).
Shen, X. et al. Nonlinear dynamics of multi-omics profiles during human aging. Nat. Aging 4, 1619–1634 (2024).
Hai, L., Jiang, Z., Zhang, H. & Sun, Y. From multi-omics to predictive biomarker: AI in tumor microenvironment. Front. Immunol. 15, 1514977 (2024).
Wu, Y. & Xie, L. AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput. Struct. Biotechnol. J. 27, 265–277 (2025).
Cui, H. et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat. Methods 21, 1470–1480 (2024).
Li, J. et al. Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer. Semin. Cancer Biol. 91, 35–49 (2023).
Giudice, V. et al. Aptamer-based proteomics of serum and plasma in acquired aplastic anemia. Exp. Hematol. 68, 38–50 (2018).
Saettini, F. et al. Biallelic PI4KA mutations disrupt B-cell metabolism and cause B-cell lymphopenia and hypogammaglobulinemia. J. Clin. Immunol. 45, 15 (2024).
Li, W. et al. Multi-omics research strategies in ischemic stroke: a multidimensional perspective. Ageing Res. Rev. 81, 101730 (2022).
Yang, H. et al. From multi-omics data to the cancer druggable gene discovery: a novel machine learning-based approach. Brief. Bioinform. 24, bbac528 (2023).
Jiang, W., Ye, W., Tan, X. & Bao, Y. J. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review. BioData Min. 18, 27 (2025).
Zielinski, J. M., Luke, J. J., Guglietta, S. & Krieg, C. High Throughput multi-omics approaches for clinical trial evaluation and drug discovery. Front. Immunol. 12, 590742 (2021).
Leppä, A. M. et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat. Genet. 56, 2790–2803 (2024).
Nishide, M. et al. Single-cell multi-omics analysis identifies two distinct phenotypes of newly-onset microscopic polyangiitis. Nat. Commun. 14, 5789 (2023).
Baalbaki, N. et al. The omics landscape of long COVID—a comprehensive systematic review to advance biomarker, target and drug discovery. Allergy 80, 932–948 (2025).
Rasooly, D., Pereira, A. C. & Joseph, J. Drug discovery and development for heart failure using multi-omics approaches. Int. J. Mol. Sci. 26, 2703 (2025).
Pacini, C. et al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell 42, 301–316.e309 (2024).
Bayat, A. et al. New insights into colorectal cancer through the lens of precision oncology and personalized medicine: multi-omics helps aging of predisposed people. Curr. Aging Sci. 18, 193–210 (2024).
Chen, C. et al. Applications of multi-omics analysis in human diseases. MedComm 4, e315 (2023).
Bai, Y. et al. Identification of drug targets for Sjögren’s syndrome: multi-omics Mendelian randomization and colocalization analyses. Front. Immunol. 15, 1419363 (2024).
Huang, X. et al. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell 42, 552–567.e556 (2024).
Si, S., Liu, H., Xu, L. & Zhan, S. Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome. Genome Med. 16, 84 (2024).
Mondal, R. et al. Applications of clustered regularly interspaced short palindromic repeats (CRISPR) as a genetic scalpel for the treatment of cancer: a translational narrative review. Cureus 15, e50031 (2023).
Kampmann, M. CRISPR-based functional genomics for neurological disease. Nat. Rev. Neurol. 16, 465–480 (2020).
MacLeod, G. et al. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 27, 971–986.e979 (2019).
McLean, B. et al. A CRISPR path to finding vulnerabilities and solving drug resistance: targeting the diverse cancer landscape and its ecosystem. Adv. Genet. 3, 2200014 (2022).
Jin, Y. et al. Application and progress of CRISPR/Cas9 gene editing in B-cell lymphoma: a narrative review. Transl. Cancer Res. 13, 1584–1595 (2024).
Katti, A. et al. CRISPR in cancer biology and therapy. Nat. Rev. Cancer 22, 259–279 (2022).
Xu, Z. et al. Structural variants drive context-dependent oncogene activation in cancer. Nature 612, 564–572 (2022).
Bian, S. et al. Genetically engineered cerebral organoids model brain tumor formation. Nat. Methods 15, 631–639 (2018).
Li, S., Zhang, Z. & Han, L. 3D spheroids propel tumor characterization. Trends Cancer 6, 622–624 (2020).
Goodwin, R. J. A., Platz, S. J., Reis-Filho, J. S. & Barry, S. T. Accelerating drug development using spatial multi-omics. Cancer Discov. 14, 620–624 (2024).
Tang, W. H. W. & Koenig, W. Multiomics insights to accelerate drug development: will they hold their promises? J. Am. Coll. Cardiol. 82, 1932–1935 (2023).
Wang, F. & Barrero, C. A. Multi-omics analysis identified drug repurposing targets for chronic obstructive pulmonary disease. Int. J. Mol. Sci. 25, 11106 (2024).
Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679–683 (2021).
Fujino, T. et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J. Thorac. Oncol. 14, 1753–1765 (2019).
Baechler, S. A. et al. The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis. Nat. Commun. 10, 83 (2019).
Zhao, H. et al. APC/C-regulated CPT1C promotes tumor progression by upregulating the energy supply and accelerating the G1/S transition. Cell Commun. Signal 22, 283 (2024).
Servetto, A., Formisano, L. & Arteaga, C. L. FGFR signaling and endocrine resistance in breast cancer: challenges for the clinical development of FGFR inhibitors. Biochim Biophys. Acta Rev. Cancer 1876, 188595 (2021).
Du, P. et al. Advances in integrated multi-omics analysis for drug-target identification. Biomolecules. 14, 692 (2024).
Zhu, Q. et al. Single cell multi-omics reveal intra-cell-line heterogeneity across human cancer cell lines. Nat. Commun. 14, 8170 (2023).
Liang, W. et al. An integrated multi-omics analysis reveals osteokines involved in global regulation. Cell Metab. 36, 1144–1163.e1147 (2024).
Li, Y. et al. Unraveling the spatial organization and development of human thymocytes through integration of spatial transcriptomics and single-cell multi-omics profiling. Nat. Commun. 15, 7784 (2024).
Vandereyken, K., Sifrim, A., Thienpont, B. & Voet, T. Methods and applications for single-cell and spatial multi-omics. Nat. Rev. Genet. 24, 494–515 (2023).
Baysoy, A., Bai, Z., Satija, R. & Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 24, 695–713 (2023).
Takei, Y. et al. Spatial multi-omics reveals cell-type-specific nuclear compartments. Nature 641, 1037–1047 (2025).
Liu, X. et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J. Hematol. Oncol. 17, 72 (2024).
Sun, C. et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat. Commun. 14, 2692 (2023).
Liu, Y. et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell 43, 905–924.e906 (2025).
Hsieh, W. C. et al. Spatial multi-omics analyses of the tumor immune microenvironment. J. Biomed. Sci. 29, 96 (2022).
Qin, Y. et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis. Mol. Cancer 22, 59 (2023).
Mars, R. A. T. et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. Cell 182, 1460–1473.e1417 (2020).
Zhang, Q. et al. Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases. Gut Microbes 17, 2508426 (2025).
Zou, F. et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function. Cell Death Dis. 12, 582 (2021).
Donohoe, D. R. et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 4, 1387–1397 (2014).
Sanchez, H. N. et al. B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids. Nat. Commun. 11, 60 (2020).
Bendixen, L., Jensen, T. I. & Bak, R. O. CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi. Mol. Ther. 31, 1920–1937 (2023).
de Bakker, V., Liu, X., Bravo, A. M. & Veening, J. W. CRISPRi-seq for genome-wide fitness quantification in bacteria. Nat. Protoc. 17, 252–281 (2022).
Santinha, A. J. et al. Transcriptional linkage analysis with in vivo AAV-Perturb-seq. Nature 622, 367–375 (2023).
Replogle, J. M. et al. Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell 185, 2559–2575.e2528 (2022).
Hou, J. et al. Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection. Nat. Commun. 15, 109 (2024).
Chen, L. et al. Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction. Mol. Psychiatry 30, 2362–2371 (2025).
Heffel, M. G. et al. Temporally distinct 3D multi-omic dynamics in the developing human brain. Nature 635, 481–489 (2024).
Richetto, J. & Meyer, U. Epigenetic modifications in schizophrenia and related disorders: molecular scars of environmental exposures and source of phenotypic variability. Biol. Psychiatry 89, 215–226 (2021).
Guo, L. K. et al. Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis. Mil. Med. Res. 10, 24 (2023).
Yang, W., Liu, C., Li, Z. & Cui, M. Multi-omic biomarkers associated with multiple sclerosis: from Mendelian randomization to drug prediction. Sci. Rep. 15, 9421 (2025).
Han, Q. J. et al. PTGES2 and RNASET2 identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma: insights from proteome-wide mendelian randomization, colocalization, and MR-PheWAS analyses. Front. Pharmacol. 15, 1418560 (2024).
Xie, J. et al. Identification of genetic association between mitochondrial dysfunction and knee osteoarthritis through integrating multi-omics: a summary data-based Mendelian randomization study. Clin. Rheumatol. 43, 3487–3496 (2024).
Shi, K. et al. Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis. Cardiovasc. Diabetol. 23, 338 (2024).
Rapicavoli, R. V., Alaimo, S., Ferro, A. & Pulvirenti, A. Computational methods for drug repurposing. Adv. Exp. Med. Biol. 1361, 119–141 (2022).
Aldea, M. et al. Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? ESMO Open 8, 101642 (2023).
Lee, S. Y. et al. A proteotranscriptomic-based computational drug-repositioning method for Alzheimer’s disease. Front. Pharmacol. 10, 1653 (2019).
Xu, J. et al. Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease. Cell Rep. 41, 111717 (2022).
Albuquerque, A. M. et al. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clin. Microbiol Infect. 29, 13–21 (2023).
Karampitsakos, T. et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin. Microbiol. Infect. 29, 372–378 (2023).
Guo, H. et al. Multi-omics analyses reveal that HIV-1 alters CD4(+) T cell immunometabolism to fuel virus replication. Nat. Immunol. 22, 423–433 (2021).
Zhou, S. et al. Potential anti-liver cancer targets and mechanisms of kaempferitrin based on network pharmacology, molecular docking and experimental verification. Comput. Biol. Med. 178, 108693 (2024).
Nguyen, T. M. et al. DeCoST: a new approach in drug repurposing from control system theory. Front. Pharmacol. 9, 583 (2018).
Li, X. et al. Network pharmacology approaches for research of traditional Chinese medicines. Chin. J. Nat. Med. 21, 323–332 (2023).
Yang, S. et al. Integrated bioinformatics and multiomics reveal Liupao tea extract alleviating NAFLD via regulating hepatic lipid metabolism and gut microbiota. Phytomedicine 132, 155834 (2024).
Ye, J. et al. Multi-omics and network pharmacology study reveals the effects of Dengzhan Shengmai capsule against neuroinflammatory injury and thrombosis induced by ischemic stroke. J. Ethnopharmacol. 305, 116092 (2023).
Mokou, M. et al. A drug repurposing pipeline based on bladder cancer integrated proteotranscriptomics signatures. Methods Mol. Biol. 2684, 59–99 (2023).
Timilsina, S. et al. The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. Cancer Lett. 540, 215717 (2022).
Kandela, I. & Aird, F. Replication study: discovery and preclinical validation of drug indications using compendia of public gene expression data. eLife 6, e17044 (2017).
Lee, S. et al. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nat. Med. 30, 3196–3208 (2024).
Daher, A. & de Groot, J. Rapid identification and validation of novel targeted approaches for glioblastoma: a combined ex vivo-in vivo pharmaco-omic model. Exp. Neurol. 299, 281–288 (2018).
Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
Aydin, B. et al. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors. J. Endocrinol. Invest. 46, 727–747 (2023).
Boso, D. et al. Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts. J. Exp. Clin. Cancer Res. 42, 196 (2023).
Liu, Y. et al. High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue. Cell 183, 1665–1681.e1618 (2020).
Miller, B. F. et al. Reference-free cell type deconvolution of multi-cellular pixel-resolution spatially resolved transcriptomics data. Nat. Commun. 13, 2339 (2022).
Zhang, S. L. et al. Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota. Nat. Metab. 6, 1991–2009 (2024).
Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199–1207 (2020).
Pan, S. et al. Metabolomics-driven approaches for identifying therapeutic targets in drug discovery. MedComm 5, e792 (2024).
Serral, F. et al. From genome to drugs: new approaches in antimicrobial discovery. Front. Pharmacol. 12, 647060 (2021).
Zhong-gen, Z. Advances in biosynthesis and regulation of the active ingredient of Salvia miltiorrhiza based on multi-omics approach. Acta Pharm. Sin. 55(12), 2892–2903 (2020).
Yuan, Z. et al. Celastrol combats methicillin-resistant Staphylococcus aureus by targeting Δ(1) -pyrroline-5-carboxylate dehydrogenase. Adv. Sci. 10, e2302459 (2023).
Soares, N. C. et al. Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach. J. Proteom. 265, 104660 (2022).
Wu, L. et al. Glycyrrhiza, a commonly used medicinal herb: review of species classification, pharmacology, active ingredient biosynthesis, and synthetic biology. J. Adv. Res. 75, 249–270 (2024).
Wang, Y., Shi, Y. N., Xiang, H. & Shi, Y. M. Exploring nature’s battlefield: organismic interactions in the discovery of bioactive natural products. Nat. Prod. Rep. 41, 1630–1651 (2024).
Palazzotto, E., Tong, Y., Lee, S. Y. & Weber, T. Synthetic biology and metabolic engineering of actinomycetes for natural product discovery. Biotechnol. Adv. 37, 107366 (2019).
Ding, X. et al. Multiple mitochondria-targeted components screened from Sini decoction improved cardiac energetics and mitochondrial dysfunction to attenuate doxorubicin-induced cardiomyopathy. Theranostics 13, 510–530 (2023).
Ma, C. et al. Qijiao Shengbai Capsule alleviated leukopenia by interfering leukotriene pathway: integrated network study of multi-omics. Phytomedicine 128, 155424 (2024).
Cheng, L. et al. The protective role of commensal gut microbes and their metabolites against bacterial pathogens. Gut Microbes 16, 2356275 (2024).
Castelo, J. et al. The microbiota metabolite, phloroglucinol, confers long-term protection against inflammation. Gut Microbes 16, 2438829 (2024).
Liu, J. R. et al. Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation. Cell Mol. Life Sci. 78, 909–922 (2021).
Vogel, C. F. A., Van Winkle, L. S., Esser, C. & Haarmann-Stemmann, T. The aryl hydrocarbon receptor as a target of environmental stressors— implications for pollution mediated stress and inflammatory responses. Redox Biol. 34, 101530 (2020).
Liu, N. N. et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat. Microbiol 7, 238–250 (2022).
Gao, W. et al. Multimodal metagenomic analysis reveals microbial single nucleotide variants as superior biomarkers for early detection of colorectal cancer. Gut Microbes 15, 2245562 (2023).
Ma, A., Xin, G. & Ma, Q. The use of single-cell multi-omics in immuno-oncology. Nat. Commun. 13, 2728 (2022).
Collora, J. A. et al. Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. Immunity 55, 1013–1031.e1017 (2022).
Rausch, J. W. et al. HIV expression in infected T cell clones. Viruses 16, 108 (2024).
Unterman, A. et al. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat. Commun. 13, 440 (2022).
Anglada-Girotto, M. et al. Combining CRISPRi and metabolomics for functional annotation of compound libraries. Nat. Chem. Biol. 18, 482–491 (2022).
Mitchell, D. C. et al. A proteome-wide atlas of drug mechanism of action. Nat. Biotechnol. 41, 845–857 (2023).
Yang, C. et al. Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes. Genome Med. 14, 140 (2022).
Chen, P. et al. Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease. J. Pharm. Anal. 14, 100910 (2024).
Ji, S. et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci. Transl. Med. 15, eadg3358 (2023).
Waldenmaier, H. E. et al. “Lab of the future”─today: fully automated system for high-throughput mass spectrometry analysis of biotherapeutics. J. Am. Soc. Mass Spectrom. 34, 1073–1085 (2023).
Howard, J. & Reiber, J. H. C. Automated analysis of coronary angiograms using artificial intelligence: a window into the cath lab of the future. EuroIntervention 17, 16–17 (2021).
Xiong, Z. et al. Facing small and biased data dilemma in drug discovery with enhanced federated learning approaches. Sci. China Life Sci. 65, 529–539 (2022).
Xiong, G. et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49, W5–w14 (2021).
Qiao, J. et al. AI-based R&D for frozen and thawed meat: research progress and future prospects. Compr. Rev. Food Sci. Food Saf. 23, e70016 (2024).
Tong, L. et al. Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. IEEE Rev. Biomed. Eng. 17, 80–97 (2024).
Yang, Z., Guan, F., Bronk, L. & Zhao, L. Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: a multidimensional perspective. Pharm. Ther. 254, 108591 (2024).
Li, L., Sun, M., Wang, J. & Wan, S. Multi-omics based artificial intelligence for cancer research. Adv. Cancer Res. 163, 303–356 (2024).
Qiu, Y. & Cheng, F. Artificial intelligence for drug discovery and development in Alzheimer’s disease. Curr. Opin. Struct. Biol. 85, 102776 (2024).
Choi, S., Adams, A. M. & Chibale, K. Special issue: exploring the use of AI/ML technologies in medicinal chemistry and drug discovery. ACS Med. Chem. Lett. 16, 174 (2025).
Sumathi, S. et al. A review on deep learning-driven drug discovery: strategies, tools and applications. Curr. Pharm. Des. 29, 1013–1025 (2023).
Gangwal, A. et al. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Front. Pharmacol. 15, 1331062 (2024).
Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702.e613 (2020).
Liu, G. et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nat. Chem. Biol. 19, 1342–1350 (2023).
Yang, K. et al. Analyzing learned molecular representations for property prediction. J. Chem. Inf. Model. 59, 3370–3388 (2019).
Luttens, A. et al. Rapid traversal of vast chemical space using machine learning-guided docking screens. Nat. Comput. Sci. 5, 301–312 (2025).
Patronov, A., Papadopoulos, K. & Engkvist, O. Has artificial intelligence impacted drug discovery? Methods Mol. Biol. 2390, 153–176 (2022).
Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463–477 (2019).
Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63–75 (2025).
Zhavoronkov, A. et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat. Biotechnol. 37, 1038–1040 (2019).
Li, X. S. et al. Multiphysical graph neural network (MP-GNN) for COVID-19 drug design. Brief. Bioinform. 23, bbac231 (2022).
Wong, F. et al. An explainable deep learning platform for molecular discovery. Nat. Protoc. 20, 1020–1056 (2025).
Fotis, C., Meimetis, N., Sardis, A. & Alexopoulos, L. G. DeepSIBA: chemical structure-based inference of biological alterations using deep learning. Mol. Omics 17, 108–120 (2021).
Liu, G. & Stokes, J. M. A brief guide to machine learning for antibiotic discovery. Curr. Opin. Microbiol. 69, 102190 (2022).
Wong, F. et al. Discovery of a structural class of antibiotics with explainable deep learning. Nature 626, 177–185 (2024).
Zhan, H., Zhu, X., Qiao, Z. & Hu, J. Graph neural tree: a novel and interpretable deep learning-based framework for accurate molecular property predictions. Anal. Chim. Acta 1244, 340558 (2023).
Deng, D. et al. XGraphBoost: extracting graph neural network-based features for a better prediction of molecular properties. J. Chem. Inf. Model. 61, 2697–2705 (2021).
Olivecrona, M., Blaschke, T., Engkvist, O. & Chen, H. Molecular de-novo design through deep reinforcement learning. J. Cheminform. 9, 48 (2017).
Maziarka, Ł et al. Mol-CycleGAN: a generative model for molecular optimization. J. Cheminform. 12, 2 (2020).
Tu, X. et al. Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model. Chin. Med. J. 138, 172–184 (2025).
Wang, N., Dong, J. & Ouyang, D. AI-directed formulation strategy design initiates rational drug development. J. Control. Release 378, 619–636 (2025).
Gold, E. R. & Cook-Deegan, R. AI drug development’s data problem. Science 388, 131 (2025).
Cyranoski, D. AI drug discovery booms in China. Nat. Biotechnol. 39, 900–902 (2021).
Wang, Y., Yang, Z. & Yao, Q. Accurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning. Commun. Med. 4, 59 (2024).
Zhang, Y. et al. Emerging drug interaction prediction enabled by a flow-based graph neural network with biomedical network. Nat. Comput. Sci. 3, 1023–1033 (2023).
Li, F. et al. DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras. Brief. Bioinform. 25, bbae358 (2024).
Alakhdar, A., Poczos, B. & Washburn, N. Diffusion models in de novo drug design. J. Chem. Inf. Model. 64, 7238–7256 (2024).
Wei, X. et al. Fragment-based discovery of small molecule inhibitors of the HDGFRP2 PWWP domain. FEBS Lett. 598, 2533–2543 (2024).
Wan, X. et al. An inductive graph neural network model for compound-protein interaction prediction based on a homogeneous graph. Brief. Bioinform. 23, bbac073 (2022).
Zhang, Z. et al. Graph neural network approaches for drug-target interactions. Curr. Opin. Struct. Biol. 73, 102327 (2022).
Han, K. et al. A review of approaches for predicting drug-drug interactions based on machine learning. Front. Pharmacol. 12, 814858 (2021).
Wang, N. N. et al. Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes. J. Cheminform. 14, 23 (2022).
Lin, X. et al. Comprehensive evaluation of deep and graph learning on drug-drug interactions prediction. Brief. Bioinform. 24, bbad235 (2023).
Nyamabo, A. K., Yu, H. & Shi, J. Y. SSI-DDI: substructure-substructure interactions for drug-drug interaction prediction. Brief. Bioinform. 22, bbab133 (2021).
Yan, X., Gu, C., Feng, Y. & Han, J. Predicting drug-drug interaction with graph mutual interaction attention mechanism. Methods 223, 16–25 (2024).
Dmitriev, A. V. et al. Drug-drug interaction prediction using PASS. SAR QSAR Environ. Res. 30, 655–664 (2019).
Yasir, M. et al. Machine learning-based drug repositioning of novel janus kinase 2 inhibitors utilizing molecular docking and molecular dynamic simulation. J. Chem. Inf. Model. 63, 6487–6500 (2023).
J, S. G., P, D. & P, E. Enhancing drug discovery in schizophrenia: a deep learning approach for accurate drug-target interaction prediction – DrugSchizoNet. Comput. Methods Biomech. Biomed. Engin. 28, 170–187 (2025).
Zhang, Y. et al. Neural network-based approaches for biomedical relation classification: a review. J. Biomed. Inform. 99, 103294 (2019).
Shen, Z. A. et al. NPI-GNN: Predicting ncRNA-protein interactions with deep graph neural networks. Brief. Bioinform. 22, bbab051 (2021).
Zhao, Y. et al. Drug-drug interaction prediction: databases, web servers and computational models. Brief. Bioinform. 25, bbad445 (2023).
Kavuluru, R., Rios, A. & Tran, T. Extracting drug-drug interactions with word and character-level recurrent neural networks. Proc. IEEE Int. Conf. Health. Inf. 2017, 5–12 (2017).
You, Y., Lu, C., Wang, W. & Tang, C. K. Relative CNN-RNN: learning relative atmospheric visibility from images. IEEE Trans. Image Process. 28, 45–55 (2019).
Wang, J. & Guo, X. Automated detection of myocardial infarction based on an improved state refinement module for LSTM/GRU. Artif. Intell. Med. 152, 102865 (2024).
Wang, J. et al. Visual analytics for RNN-based deep reinforcement learning. IEEE Trans. Vis. Comput. Graph 28, 4141–4155 (2022).
Khaki, S., Wang, L. & Archontoulis, S. V. A CNN-RNN framework for crop yield prediction. Front. Plant Sci. 10, 1750 (2019).
Zhang, Y. et al. A hybrid model based on neural networks for biomedical relation extraction. J. Biomed. Inform. 81, 83–92 (2018).
Zaikis, D. & Vlahavas, I. TP-DDI: transformer-based pipeline for the extraction of Drug-Drug Interactions. Artif. Intell. Med. 119, 102153 (2021).
Zaikis, D. & Vlahavas, I. TransformDDI: the transformer-based joint multi-task model for end-to-end drug-drug interaction extraction. IEEE J. Biomed. Health Inform. 29, 3045–3056 (2024).
Järvinen, E. et al. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. Clin. Pharmacol. Ther. 113, 1284–1294 (2023).
Colón Ortiz, R. et al. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier. Fluids Barriers CNS 21, 5 (2024).
Cao, P. Y. et al. Group graph: a molecular graph representation with enhanced performance, efficiency and interpretability. J. Cheminform. 16, 133 (2024).
Yin, H. et al. Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions. Chem. Biol. Interact. 395, 111023 (2024).
Galetin, A., Burt, H., Gibbons, L. & Houston, J. B. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. 34, 166–175 (2006).
Prieto Garcia, L. et al. Physiologically based pharmacokinetic model of itraconazole and two of its metabolites to improve the predictions and the mechanistic understanding of CYP3A4 drug-drug interactions. Drug Metab. Dispos. 46, 1420–1433 (2018).
Han, H. et al. Employing automated machine learning (AutoML) methods to facilitate the in silico ADMET properties prediction. J. Chem. Inf. Model. 65, 3215–3225 (2025).
Menestrina, L. et al. Refined ADME profiles for ATC drug classes. Pharmaceutics. 17, 308 (2025).
Williams, D. P. et al. Predicting drug-induced liver injury with Bayesian machine learning. Chem. Res. Toxicol. 33, 239–248 (2020).
Semenova, E., Afzal, W. D. & Lazic, A. M. SE. A Bayesian neural network for toxicity prediction. Comput. Toxicol. 16, 100133 (2020).
Smith, G. F. Artificial intelligence in drug safety and metabolism. Methods Mol. Biol. 2390, 483–501 (2022).
Mamoshina, P., Bueno-Orovio, A. & Rodriguez, B. Dual transcriptomic and molecular machine learning predicts all major clinical forms of drug cardiotoxicity. Front. Pharmacol. 11, 639 (2020).
Hammann, F., Schöning, V. & Drewe, J. Prediction of clinically relevant drug-induced liver injury from structure using machine learning. J. Appl. Toxicol. 39, 412–419 (2019).
Joshi, P. V. M. & Mukherjee, A. A knowledge graph embedding based approach to predict the adverse drug reactions using a deep neural network. J. Biomed. Inform. 132, 104122 (2022).
Rao, M. et al. Artificial intelligence and machine learning models for predicting drug-induced kidney injury in small molecules. Pharmaceuticals 17, 1550 (2024).
Liu, J. et al. In silico off-target profiling for enhanced drug safety assessment. Acta Pharm. Sin. B 14, 2927–2941 (2024).
Kp Jayatunga, M. et al. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discov. Today 29, 104009 (2024).
Catacutan, D. B., Alexander, J., Arnold, A. & Stokes, J. M. Machine learning in preclinical drug discovery. Nat. Chem. Biol. 20, 960–973 (2024).
Cai, H. et al. FP-GNN: a versatile deep learning architecture for enhanced molecular property prediction. Brief. Bioinform. 23, bbac408 (2022).
Ashe, E. C., Comeau, A. M., Zejdlik, K. & O’Connell, S. P. Characterization of bacterial community dynamics of the human mouth throughout decomposition via metagenomic, metatranscriptomic, and culturing techniques. Front. Microbiol. 12, 689493 (2021).
Zhai, Y., Chen, L. & Deng, M. scGAD: a new task and end-to-end framework for generalized cell type annotation and discovery. Brief. Bioinform. 24, bbad045 (2023).
Wang, B. et al. STCGAN: a novel cycle-consistent generative adversarial network for spatial transcriptomics cellular deconvolution. Brief. Bioinform. 26, bbae670 (2024).
Mswahili, M. E. et al. Positional embeddings and zero-shot learning using BERT for molecular-property prediction. J. Cheminform. 17, 17 (2025).
Hao, M. et al. Large-scale foundation model on single-cell transcriptomics. Nat. Methods 21, 1481–1491 (2024).
Zhai, Y., Chen, L. & Deng, M. scBOL: a universal cell type identification framework for single-cell and spatial transcriptomics data. Brief. Bioinform. 25, bbae188 (2024).
Guo, Q., Yuan, M., Zhang, L. & Deng, M. scPLAN: a hierarchical computational framework for single transcriptomics data annotation, integration and cell-type label refinement. Brief. Bioinform. 25, bbae305 (2024).
Rozera, T., Pasolli, E., Segata, N. & Ianiro, G. Machine learning and artificial intelligence in the multi-omics approach to gut microbiota. Gastroenterology. 169, 487–501 (2025).
Dakal, T. C., Xu, C. & Kumar, A. Advanced computational tools, artificial intelligence and machine-learning approaches in gut microbiota and biomarker identification. Front. Med. Technol. 6, 1434799 (2024).
Majidova, K. et al. Role of digital health and artificial intelligence in inflammatory bowel disease: a scoping review. Genes 12, 1465 (2021).
Zheng, J. et al. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat. Med. 30, 3555–3567 (2024).
Huang, Q., Zhang, X. & Hu, Z. Application of artificial intelligence modeling technology based on multi-omics in noninvasive diagnosis of inflammatory bowel disease. J. Inflamm. Res. 14, 1933–1943 (2021).
Xu, Z. et al. Precision medicine in colorectal cancer: leveraging multi-omics, spatial omics, and artificial intelligence. Clin. Chim. Acta 559, 119686 (2024).
Kann, B. H., Hosny, A. & Aerts, H. Artificial intelligence for clinical oncology. Cancer Cell 39, 916–927 (2021).
Tanaka, I., Furukawa, T. & Morise, M. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell Int. 21, 454 (2021).
Barroso, R. A. et al. Unlocking antimicrobial peptides: in silico proteolysis and artificial intelligence-driven discovery from cnidarian omics. Molecules. 30, 550 (2025).
Feng, J. et al. A synthetic antibiotic class with a deeply-optimized design for overcoming bacterial resistance. Nat. Commun. 15, 6040 (2024).
Oh, H. S. et al. Organ aging signatures in the plasma proteome track health and disease. Nature 624, 164–172 (2023).
Duggan, M. R. & Walker, K. A. Organ-specific aging in the plasma proteome predicts disease. Trends Mol. Med. 30, 423–424 (2024).
Li, T. et al. Integrating machine learning and multi-omics analysis to reveal nucleotide metabolism-related immune genes and their functional validation in ischemic stroke. Front. Immunol. 16, 1561544 (2025).
Zhao, Y. et al. Integrating machine learning and single-cell transcriptomic analysis to identify potential biomarkers and analyze immune features of ischemic stroke. Sci. Rep. 14, 26069 (2024).
Hebron, M. et al. Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. J. Neuroimmunol. 311, 1–9 (2017).
Kortagere, S. et al. Identification of novel allosteric modulators of glutamate transporter EAAT2. ACS Chem. Neurosci. 9, 522–534 (2018).
Liu, B. et al. Retrosynthetic reaction prediction using neural sequence-to-sequence models. ACS Cent. Sci. 3, 1103–1113 (2017).
Wang, Y. et al. Retrosynthesis prediction with an interpretable deep-learning framework based on molecular assembly tasks. Nat. Commun. 14, 6155 (2023).
Hu, J., Luo, Y. & Wang, X. Multi-omics analysis of druggable genes to facilitate Alzheimer’s disease therapy: a multi-cohort machine learning study. J. Prev. Alzheimers Dis. 12, 100128 (2025).
Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement. 9, e12385 (2023).
Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer’s disease. Nat. Commun. 12, 1033 (2021).
Cheng, F. et al. Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease. Cell Rep. Med. 5, 101379 (2024).
Zhou, Y. et al. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery. Alzheimers Res. Ther. 13, 24 (2021).
Zulhafiz, N. A., Teoh, T. C., Chin, A. V. & Chang, S. W. Drug repurposing using artificial intelligence, molecular docking, and hybrid approaches: a comprehensive review in general diseases vs Alzheimer’s disease. Comput. Methods Prog. Biomed. 261, 108604 (2025).
Wan, Z. et al. Applications of artificial intelligence in drug repurposing. Adv. Sci. 12, e2411325 (2025).
Li, V. O. K. et al. DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease. Sci. Rep. 15, 2093 (2025).
Shin, M. K. et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 184, 2715–2732.e2723 (2021).
Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154–1162 (2015).
Fang, J. et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nat. Aging 1, 1175–1188 (2021).
Paranjpe, M. D., Taubes, A. & Sirota, M. Insights into computational drug repurposing for neurodegenerative disease. Trends Pharmacol. Sci. 40, 565–576 (2019).
Sun, X. et al. Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine. J. Headache Pain. 25, 117 (2024).
Bai, C. et al. Machine learning-enabled drug-induced toxicity prediction. Adv. Sci. 12, e2413405 (2025).
Monzel, A. S. et al. Machine learning-assisted neurotoxicity prediction in human midbrain organoids. Parkinsonism Relat. Disord. 75, 105–109 (2020).
Kuusisto, F. et al. Machine learning to predict developmental neurotoxicity with high-throughput data from 2D bio-engineered tissues. Proc. Int. Conf. Mach. Learn. Appl. 2019, 293–298 (2019).
Zhao, X. et al. Machine learning modeling and insights into the structural characteristics of drug-induced neurotoxicity. J. Chem. Inf. Model. 62, 6035–6045 (2022).
Lee, B. et al. A deep learning approach with data augmentation to predict novel spider neurotoxic peptides. Int. J. Mol. Sci. 22, 12291 (2021).
Zeng, X. et al. Accurate prediction of molecular targets using a self-supervised image representation learning framework. Res. Sq. 3, 1477870 (2022).
Parikh, J. et al. Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action. J. Pharmacokinet. Pharmacodyn. 49, 51–64 (2022).
Cummings, J. Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin. Transl. Sci. 11, 147–152 (2018).
Shaker, B. et al. LightBBB: computational prediction model of blood-brain-barrier penetration based on LightGBM. Bioinformatics 37, 1135–1139 (2021).
Saxena, D., Sharma, A., Siddiqui, M. H. & Kumar, R. Blood brain barrier permeability prediction using machine learning techniques: an update. Curr. Pharm. Biotechnol. 20, 1163–1171 (2019).
Nada, H. et al. Machine learning-based approach to developing potent EGFR inhibitors for breast cancer-design, synthesis, and in vitro evaluation. ACS Omega 8, 31784–31800 (2023).
Bararia, A. et al. A multi-phase approach using supervised algorithms and clinical models to generate high-accuracy signatures for pancreatic cancer. Comput. Biol. Med. 194, 110559 (2025).
Sharma, S., Singh, R., Kant, S. & Mishra, M. K. Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer. Comput. Biol. Med. 193, 110432 (2025).
Yan, H., Ji, X. & Li, B. Advancing personalized, predictive, and preventive medicine in bladder cancer: a multi-omics and machine learning approach for novel prognostic modeling, immune profiling, and therapeutic target discovery. Front. Immunol. 16, 1572034 (2025).
Cheerla, A. & Gevaert, O. Deep learning with multimodal representation for pancancer prognosis prediction. Bioinformatics 35, i446–i454 (2019).
Biswas, N. & Chakrabarti, S. Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Front. Oncol. 10, 588221 (2020).
Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct. Target Ther. 9, 170 (2024).
He, Z. et al. Multi-omics and tumor immune microenvironment characterization of a prognostic model based on aging-related genes in melanoma. Am. J. Cancer Res. 14, 1052–1070 (2024).
Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).
Mehrotra, S., Sharma, S. & Pandey, R. K. A journey from omics to clinicomics in solid cancers: success stories and challenges. Adv. Protein Chem. Struct. Biol. 139, 89–139 (2024).
Patkulkar, P. A., Subbalakshmi, A. R., Jolly, M. K. & Sinharay, S. Mapping spatiotemporal heterogeneity in tumor profiles by integrating high-throughput imaging and omics analysis. ACS Omega 8, 6126–6138 (2023).
Feng, Y. et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients. Nat. Commun. 15, 10259 (2024).
Cembrowska-Lech, D. et al. An integrated multi-omics and artificial intelligence framework for advance plant phenotyping in horticulture. Biology 12, 1298 (2023).
Imai, M. et al. Artificial intelligence-powered human epidermal growth factor receptor 2 and tumor microenvironment analysis in human epidermal growth factor receptor 2-amplified metastatic colorectal cancer: exploratory analysis of phase II TRIUMPH trial. JCO Precis. Oncol. 9, e2400385 (2025).
Kumar, H. et al. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer J. 12, 39 (2022).
Chen, W. et al. Integrating radiomics with genomics for non-small cell lung cancer survival analysis. J. Oncol. 2022, 5131170 (2022).
Quek, C. et al. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep. 43, 114392 (2024).
Hu, T. et al. Multi-omics and single-cell analysis reveals machine learning-based pyrimidine metabolism-related signature in the prognosis of patients with lung adenocarcinoma. Int. J. Med. Sci. 22, 1375–1392 (2025).
Kan, Z. et al. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors. Nat. Commun. 16, 932 (2025).
Au Yeung, V. P. W. et al. Computational approaches identify a transcriptomic fingerprint of drug-induced structural cardiotoxicity. Cell Biol. Toxicol. 40, 50 (2024).
Zhu, Z. et al. Two-dimensional deep learning frameworks for drug-induced cardiotoxicity detection. ACS Sens 9, 3316–3326 (2024).
Yu, L., Xu, Z., Qiu, W. & Xiao, X. MSDSE: predicting drug-side effects based on multi-scale features and deep multi-structure neural network. Comput. Biol. Med. 169, 107812 (2024).
Uner, O. C. et al. DeepSide: a deep learning approach for drug side effect prediction. IEEE/ACM Trans. Comput. Biol. Bioinform. 20, 330–339 (2023).
Wei, J. et al. GCFMCL: predicting miRNA-drug sensitivity using graph collaborative filtering and multi-view contrastive learning. Brief. Bioinform. 24, bbad247 (2023).
Mason, D. M. et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat. Biomed. Eng. 5, 600–612 (2021).
Sinha, S. et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat. Cancer 5, 938–952 (2024).
Joshi, A., Rienks, M., Theofilatos, K. & Mayr, M. Systems biology in cardiovascular disease: a multiomics approach. Nat. Rev. Cardiol. 18, 313–330 (2021).
Kiessling, P. & Kuppe, C. Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases. Genome Med. 16, 14 (2024).
Xu, Y. et al. An atlas of genetic scores to predict multi-omic traits. Nature 616, 123–131 (2023).
Ouwerkerk, W. et al. Multiomics analysis provides novel pathways related to progression of heart failure. J. Am. Coll. Cardiol. 82, 1921–1931 (2023).
Yang, J. et al. Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy. Sci. Transl. Med. 14, eabl5654 (2022).
Theodoris, C. V. et al. Transfer learning enables predictions in network biology. Nature 618, 616–624 (2023).
Shi, H. & Zhang, S. Accurate prediction of anti-hypertensive peptides based on convolutional neural network and gated recurrent unit. Interdiscip. Sci. 14, 879–894 (2022).
Ma, C., Zhou, Z., Liu, H. & Koslicki, D. KGML-xDTD: a knowledge graph-based machine learning framework for drug treatment prediction and mechanism description. Gigascience 12, giad057 (2022).
Preuss, M. et al. Design of the coronary artery disease genome-wide replication and meta-analysis (CARDIoGRAM) study: a genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ. Cardiovasc. Genet. 3, 475–483 (2010).
Musunuru, K. et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714–719 (2010).
Linsel-Nitschke, P. et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 208, 183–189 (2010).
Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57–63 (2009).
Wu, P. Y. et al. Cardiovascular transcriptomics and epigenomics using next-generation sequencing: challenges, progress, and opportunities. Circ. Cardiovasc. Genet. 7, 701–710 (2014).
Mohammadi, P. et al. Genetic regulatory variation in populations informs transcriptome analysis in rare disease. Science 366, 351–356 (2019).
Franzén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353, 827–830 (2016).
Human genomics The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
Khan, S. U. et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ 377, e069116 (2022).
Ren, Z. H. et al. DeepMPF: deep learning framework for predicting drug-target interactions based on multi-modal representation with meta-path semantic analysis. J. Transl. Med. 21, 48 (2023).
Karlstädt, A. et al. CardioNet: a human metabolic network suited for the study of cardiomyocyte metabolism. BMC Syst. Biol. 6, 114 (2012).
Edwards, L. M. et al. Genome-scale methods converge on key mitochondrial genes for the survival of human cardiomyocytes in hypoxia. Circ. Cardiovasc. Genet. 7, 407–415 (2014).
Zong, N. et al. Advancing efficacy prediction for EHR-based emulated trials in repurposing heart failure therapies. NPJ Digit. Med. 8, 306 (2025).
Wang, L. et al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: the Mayo-Baylor RIGHT 10K Study. Genet. Med. 24, 1062–1072 (2022).
Tan, H. et al. Machine learning approach reveals microbiome, metabolome, and lipidome profiles in type 1 diabetes. J. Adv. Res. 64, 213–221 (2024).
Allesøe, R. L. et al. Author Correction: Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models. Nat. Biotechnol. 41, 1026 (2023).
Shapiro, M. R. et al. Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes. Diabetologia 68, 477–494 (2025).
Zhang, F. et al. Harnessing omics data for drug discovery and development in ovarian aging. Hum. Reprod. Update 31, 240–268 (2025).
Jusoh, A. S. et al. How generative artificial intelligence can transform drug discovery? Eur. J. Med. Chem. 295, 117825 (2025).
Rabaan, A. A. et al. Omics approaches in drug development against leishmaniasis: current scenario and future prospects. Pathogens 12, 39 (2022).
Hay, M. et al. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).
Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence for clinical trial design. Trends Pharmacol. Sci. 40, 577–591 (2019).
Gligorijevic, J. et al. Optimizing clinical trials recruitment via deep learning. J. Am. Med. Inform. Assoc. 26, 1195–1202 (2019).
Fogel, D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun. 11, 156–164 (2018).
Persidis, A. The benefits of drug repositioning. Drug Discov. World 12, 9–12 (2011).
Baldi Antognini, A., Novelli, M., Zagoraiou, M. & Vagheggini, A. Compound optimal allocations for survival clinical trials. Biom. J. 62, 1730–1746 (2020).
Perni, S., Jimenez, R. & Jagsi, R. Optimizing informed consent in cancer clinical trials. Semin. Radiat. Oncol. 33, 349–357 (2023).
Sarkar, C. et al. Artificial intelligence and machine learning technology driven modern drug discovery and development. Int. J. Mol. Sci. 24, 2026 (2023).
van der Lee, M. & Swen, J. J. Artificial intelligence in pharmacology research and practice. Clin. Transl. Sci. 16, 31–36 (2023).
Wilczok, D. & Zhavoronkov, A. Progress, pitfalls, and impact of AI-driven clinical trials. Clin. Pharmacol. Ther. 117, 887–890 (2025).
Aguado, B. A. et al. The future of sex and gender in research. Cell 187, 1354–1357 (2024).
Bewley, S., McCartney, M., Meads, C. & Rogers, A. Sex, gender, and medical data. BMJ 372, n735 (2021).
Boland, M. R., Elhadad, N. & Pratt, W. Informatics for sex- and gender-related health: understanding the problems, developing new methods, and designing new solutions. J. Am. Med. Inform. Assoc. 29, 225–229 (2022).
Park, Y. et al. Comparison of methods to reduce bias from clinical prediction models of postpartum depression. JAMA Netw. Open 4, e213909 (2021).
Zhou, W. et al. Global biobank meta-analysis initiative: powering genetic discovery across human disease. Cell Genom. 2, 100192 (2022).
Jian, X. et al. Genome-wide association study of cognitive function in diverse Hispanics/Latinos: results from the Hispanic Community Health Study/Study of Latinos. Transl. Psychiatry 10, 245 (2020).
Migliozzi, S. et al. Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nat. Cancer 4, 181–202 (2023).
Bravo González-Blas, C. et al. Single-cell spatial multi-omics and deep learning dissect enhancer-driven gene regulatory networks in liver zonation. Nat. Cell Biol. 26, 153–167 (2024).
Fatima, I. et al. Breakthroughs in AI and multi-omics for cancer drug discovery: a review. Eur. J. Med. Chem. 280, 116925 (2024).
Wen, Z. et al. Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets. J. Transl. Med. 23, 337 (2025).
Gao, R. et al. Secreted MUP1 that reduced under ER stress attenuates ER stress induced insulin resistance through suppressing protein synthesis in hepatocytes. Pharmacol. Res. 187, 106585 (2023).
Wang, T. et al. Identification of serum biomarkers and therapeutic targets for aortic diseases in obesity through multi-omics analysis. J. Thorac. Dis. 16, 8435–8449 (2024).
Chen, Y. X. et al. An integrative multi-omics network-based approach identifies key regulators for breast cancer. Comput. Struct. Biotechnol. J. 18, 2826–2835 (2020).
Kim, N. et al. CCR8 as a therapeutic novel target: omics-integrated comprehensive analysis for systematically prioritizing indications. Biomedicines 11, 2910 (2023).
Vos, W. et al. The 2000HIV study: design, multi-omics methods and participant characteristics. Front. Immunol. 13, 982746 (2022).
Yang, B. et al. NetSDR: Drug repurposing for cancers based on subtype-specific network modularization and perturbation analysis. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167688 (2025).
Zillich, E. et al. Multi-omics profiling of DNA methylation and gene expression alterations in human cocaine use disorder. Transl. Psychiatry 14, 428 (2024).
Karaosmanoglu, K., Sayar, N. A., Kurnaz, I. A. & Akbulut, B. S. Assessment of berberine as a multi-target antimicrobial: a multi-omics study for drug discovery and repositioning. OMICS 18, 42–53 (2014).
Krumm, J. et al. High-throughput screening and proteomic characterization of compounds targeting myeloid-derived suppressor cells. Mol. Cell Proteom. 22, 100632 (2023).
Hell, T. et al. Combining activity profiling with advanced annotation to accelerate the discovery of natural products targeting oncogenic signaling in melanoma. J. Nat. Prod. 85, 1540–1554 (2022).
Ory, L. et al. Targeting bioactive compounds in natural extracts—development of a comprehensive workflow combining chemical and biological data. Anal. Chim. Acta 1070, 29–42 (2019).
Zhu, J. et al. SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug-drug interaction prediction. BMC Bioinforma. 25, 39 (2024).
Wang, Z. & Wei, Z. A framework for pre-training biomedical knowledge graphs with graph neural networks. Comput. Biol. Med. 178, 108768 (2024).
He, C. et al. Multi-type feature fusion based on graph neural network for drug-drug interaction prediction. BMC Bioinforma. 23, 224 (2022).
Zhang, Y. et al. Predicting drug-drug interactions using multi-modal deep auto-encoders based network embedding and positive-unlabeled learning. Methods 179, 37–46 (2020).
Ren, Z. H. et al. BioChemDDI: predicting drug-drug interactions by fusing biochemical and structural information through a self-attention mechanism. Biology 11, 758 (2022).
Zang, X., Zhao, X. & Tang, B. Hierarchical molecular graph self-supervised learning for property prediction. Commun. Chem. 6, 34 (2023).
Wang, Z. et al. DEML: drug synergy and interaction prediction using ensemble-based multi-task learning. Molecules 28, 844 (2023).
Coaviche-Yoval, A. et al. In silico and in vivo neuropharmacological evaluation of two γ-amino acid isomers derived from 2,3-disubstituted benzofurans, as ligands of GluN1-GluN2A NMDA receptor. Amino Acids 54, 215–228 (2022).
Tang, Y. et al. Structure-based discovery of CZL80, a caspase-1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility. Br. J. Pharmacol. 177, 3519–3534 (2020).
Qiang, S. J. et al. The discovery of novel PGK1 activators as apoptotic inhibiting and neuroprotective agents. Front. Pharmacol. 13, 877706 (2022).
Pandey, P. et al. Structure-based identification of potent natural product chemotypes as cannabinoid receptor 1 inverse agonists. Molecules 23, 2630 (2018).
Ozhathil, L. C. et al. Identification of potent and selective small molecule inhibitors of the cation channel TRPM4. Br. J. Pharmacol. 175, 2504–2519 (2018).
Kampen, S. et al. Structure-based discovery of negative allosteric modulators of the metabotropic glutamate receptor 5. ACS Chem. Biol. 17, 2744–2752 (2022).
Zhou, J. et al. Machine-learning-enabled virtual screening for inhibitors of lysine-specific histone demethylase 1. Molecules 26, 7492 (2021).
Wei, L. et al. Hit identification driven by combining artificial intelligence and computational chemistry methods: a PI5P4K-β case study. J. Chem. Inf. Model. 63, 5341–5355 (2023).
Reker, D., Schneider, P. & Schneider, G. Multi-objective active machine learning rapidly improves structure-activity models and reveals new protein-protein interaction inhibitors. Chem. Sci. 7, 3919–3927 (2016).
Boniolo, F. et al. Artificial intelligence in early drug discovery enabling precision medicine. Expert Opin. Drug Discov. 16, 991–1007 (2021).
Limeta, A. et al. Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors. Comput. Struct. Biotechnol. J. 21, 3912–3919 (2023).
Fountzilas, E., Tsimberidou, A. M., Vo, H. H. & Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 14, 101 (2022).
Moingeon, P., Kuenemann, M. & Guedj, M. Artificial intelligence-enhanced drug design and development: toward a computational precision medicine. Drug Discov. Today 27, 215–222 (2022).
Ahmed, Z. Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis. Prog. Mol. Biol. Transl. Sci. 190, 101–125 (2022).
Kolla, L. et al. The case for AI-driven cancer clinical trials—the efficacy arm in silico. Biochim Biophys. Acta Rev. Cancer 1876, 188572 (2021).
Hartl, D. et al. Translational precision medicine: an industry perspective. J. Transl. Med. 19, 245 (2021).
Sedano, R. et al. Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review. Ther. Adv. Gastroenterol. 18, 17562848251321915 (2025).
Wei, L. et al. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. Br. J. Radiol. 96, 20230211 (2023).
Terranova, N. & Venkatakrishnan, K. Machine learning in modeling disease trajectory and treatment outcomes: an emerging enabler for model-informed precision medicine. Clin. Pharmacol. Ther. 115, 720–726 (2024).
Lorkowski, J., Kolaszyńska, O. & Pokorski, M. Artificial intelligence and precision medicine: a perspective. Adv. Exp. Med. Biol. 1375, 1–11 (2022).